Zhihong Liu
The General Hospital of Eastern Theater Command · Jinling Hospital, China · Chinese Academy of Medical Sciences, Fuwai Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Zhihong Liu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:14 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06819514 · The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry DiseaseGuangzhou Jiayin Biotech Ltd · not yet recruiting · Fabry Disease · principal investigator
- Ph1NCT06285279 · The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney DiseasesNanjing University School of Medicine · recruiting · Lupus Nephritis, ANCA-associated Vasculitis, Membranous Nephropathy - PLA2R Induced · principal investigator
- N/ANCT06135909 · CHASE Registry of Patients With Pulmonary Hypertension Receiving Targeted TherapyChinese Pulmonary Vascular Disease Research Group · recruiting · Pulmonary Hypertension · principal investigator
- Ph1NCT05846347 · Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus ErythematosusZhejiang University · unknown · CAR-T · principal investigator
- N/ANCT05595200 · Prevalence, Phenotypes, Predictors and Prognostic Implication of Obstructive Sleep Apnea in Pulmonary HypertensionChinese Pulmonary Vascular Disease Research Group · recruiting · Sleep Apnea, Obstructive Sleep Apnea, Pulmonary Hypertension · principal investigator
- N/ANCT05569655 · Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAHChinese Pulmonary Vascular Disease Research Group · unknown · Pulmonary Arterial Hypertension, Randomized Controlled Trial · study director
- N/ANCT05566002 · Artificial Intelligence-assisted Evaluation of Pulmonary HYpertensionChinese Pulmonary Vascular Disease Research Group · recruiting · Pulmonary Hypertension, Pulmonary Arterial Hypertension · principal investigator
- N/ANCT05553015 · A Real-World Registry Investigating TReprostInil sodiUM in Pulmonary Hypertension (Re-TRIUMPH)Chinese Pulmonary Vascular Disease Research Group · unknown · Pulmonary Hypertension, Medication Therapy Management · study director
- N/ANCT05388682 · Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery InvolvementChinese Pulmonary Vascular Disease Research Group · recruiting · Takayasu Arteritis With Pulmonary Artery Involvement, Percutaneous Transluminal Pulmonary Angioplasty, PAH Targeted Medication · principal investigator
- N/ANCT04741022 · Influence of Obstructive Sleep Apnea on the Severity of Coronary Artery DiseaseChinese Pulmonary Vascular Disease Research Group · completed · Coronary Artery Disease · study chair
- N/ANCT04210791 · Autologous Stem Cell Transplantation for Patients With AL AmyloidosisNanjing University School of Medicine · enrolling by invitation · AL Amyloidosis, Plasma Cell Dyscrasia · study director
- N/ANCT03828071 · Autologous Hematopoietic Stem Cell Transplantation for Refractory Lupus NephritisNanjing University School of Medicine · completed · Lupus Nephritis · principal investigator
- Ph4NCT03123406 · Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPTKyowa Kirin China Pharmaceutical Co., Ltd. · completed · Hyperparathyroidism; Secondary, Renal · study chair
- N/ANCT03066141 · Evaluation of Association Between Obstructive Sleep Apnea and the Severity of Coronary Artery DiseaseChinese Pulmonary Vascular Disease Research Group · completed · Coronary Artery Disease · study chair
- N/ANCT02298335 · Glucocorticoid in Treatment of Adult Idiopathic Nephrotic Syndrome:a Prospective Observational StudyNanjing University School of Medicine · completed · Nephrotic Syndrome,Idiopathic · study chair
- N/ANCT02294344 · The Clinical Efficacy of DFPP in Patients With AAGNZhi-Hong Liu, M.D. · terminated · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · study director
- N/ANCT02214043 · Clinical Characteristics of Acute Pulmonary Embolism in Chinese PopulationChinese Pulmonary Vascular Disease Research Group · completed · Pulmonary Embolism · study chair
- N/ANCT02061787 · the Application of Cardiopulmonary Exercise Testing in Assessment Outcome of Patients With Pulmonary HypertensionChinese Pulmonary Vascular Disease Research Group · recruiting · Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder) · study director
- N/ANCT02059993 · The Effects of Obstructive Sleep Apnea and Its Intervention on Coronary Heart DiseaseChinese Pulmonary Vascular Disease Research Group · completed · Hypertension, Metabolic Disorder · study chair
- Ph3NCT01998503 · Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL AmyloidosisNanjing University School of Medicine · completed · Amyloidosis · principal investigator
- N/ANCT01451710 · The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA NephropathyNanjing University School of Medicine · completed · IgA Nephropathy · study director
- N/ANCT01451489 · The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental GlomerulosclerosisNanjing University School of Medicine · terminated · FSGS · study director
- N/ANCT01273844 · Study of Bortezomib +HSCT in Primary Systemic Amyloidosis (AL)Zhi-Hong Liu, M.D. · completed · Amyloidosis · principal investigator
- N/ANCT01269021 · An Multi-site Prospective Study to Assess the Efficacy and Safety of MMF in the Treatment of Proliferative IgA Nephropathy(IgAN)Zhi-Hong Liu, M.D. · completed · IgA Nephropathy (IgAN) · principal investigator
- N/ANCT01161459 · Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus SteroidZhi-Hong Liu, M.D. · completed · Idiopathic Membranous Nephropathy · principal investigator
- N/ANCT01056237 · Long-Term Study of Multi-target Therapy as Maintenance Treatment for Lupus NephritisZhi-Hong Liu, M.D. · completed · Lupus Nephritis · principal investigator
- N/ANCT00876616 · Assess the Efficacy and Safety of Multi-target Therapy in Lupus NephritisZhi-Hong Liu, M.D. · completed · Lupus Nephritis · principal investigator
- N/ANCT00518362 · To Compare the Efficacy and Safety of Tripterygium (TW) Versus Valsartan in the Diabetic Nephropathy (DN)Nanjing University School of Medicine · completed · Diabetic Nephropathy · principal investigator
- Ph4NCT00518219 · To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN)Nanjing University School of Medicine · completed · Membranous Nephropathy · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:14 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:14 UTC. The ranking covers the 200 most relevant of 2004 PubMed records, and a shared surname and initials can bring in a namesake. All 2004 on PubMed
- Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.N Engl J Med · 2023287 citationsRCR 36.7
- 265 citationsRCR 35.1
- Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.JAMA Oncol · 2023155 citationsRCR 13.3
- Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.Br J Dermatol · 2023141 citationsRCR 19.2
- 139 citationsRCR 15.2
- Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial.Nat Med · 2025139 citationsRCR 29.7
- Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial.Nat Med · 2024130 citationsRCR 16.1
- 119 citationsRCR 11.8
- Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial.Nat Med · 2024116 citationsRCR 17.4
- 112 citationsRCR 7.5